Sana reports Q3 2026 progress on SC451 and SG293, NEJM data on UP421
Sana said it continues moving toward starting trials for two cell therapy candidates while reporting $121.7 million in cash as of September 30, 2026.
SEC filing
1 story
Sana said it continues moving toward starting trials for two cell therapy candidates while reporting $121.7 million in cash as of September 30, 2026.
SEC filing